SXL 05 - SelexelAlternative Names: SXL05
Latest Information Update: 08 Sep 2016
At a glance
- Originator SeleXel
- Class Antineoplastics
- Mechanism of Action RNA interference; Small interfering RNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Prostate cancer
Most Recent Events
- 08 Sep 2016 Preclinical trials in Breast cancer in France (Parenteral)
- 08 Sep 2016 Preclinical trials in Prostate cancer in France (Parenteral)